21 October 2025 - With the approval of Arbysvo for adults aged 18+, there is now a way to help protect against RSV in a population that previously did not have vaccination options.

Pfizer Canada announced today that Health Canada has approved a new indication for Abrysvo, the respiratory syncytial virus (RSV) stabilised pre-fusion F subunit bivalent vaccine, for use in adults aged 18-59 at increased risk for lower respiratory tract disease caused by RSV, in addition to existing indications of all adults over 60 and infants from birth through 6 months of age via maternal immunisation.

Read Pfizer press release